Among the most promising of the new therapies being developed for the treatment of Cystic
Fibrosis (CF) are those targeted at increasing mucosal hydration on the surface of the …

Background: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2
clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing …

Objectives. —To determine if racial-ethnic differences exist in survival, disease progression,
and development of myelosuppression in zidovudine-treated patients with advanced human …

The end of the twentieth century saw dramatic improvements in the prognosis of HIV infection
brought about by the introduction of new agents (the protease inhibitors and the non‐…

Background: Antiretroviral tolerability is a critical factor contributing to treatment outcome.
The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety …

The pharmacokinetics and safety of the L‐valyl ester pro‐drug of acyclovir, valaciclovir (256U87),
were investigated in two phase I, placebo‐controlled trials in normal volunteers. These …

Congenital infection by human cytomegalovirus (CMV) is presently the leading infectious
cause of mental retardation and congenital deafness in the United States. Live CMV vaccines …

Objectives: We evaluated virologic and immunologic responses to antiretroviral therapy in
gut-associated lymphoid tissue (GALT) compared with those found in peripheral blood. …

91 renal transplant candidates were randomised to receive Towne strain cytomegalovirus (CMV)
vaccine or placebo at least 8 weeks before transplantation. The vaccine was well …

Background . Early virological response to antiretroviral therapy is predictive of long-term
treatment outcome in therapy-naive patients. In treatment-experienced patients, such …